HOLDEMANELLA SP. Bacteria and their uses
The Holdemanella biformis strain CECT 9752 regulates the enteroendocrine system, which solves the problem of limited effectiveness of existing obesity treatment methods, achieves multi-faceted improvements to obesity and related metabolic diseases, and provides a more effective treatment plan.
Patent Information
- Application Number
- CN201980092463.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-12-26
- Filing Date
- 2019-12-24
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2039-12-24
AI Technical Summary
The existing treatment methods for obesity and its related metabolic diseases have limited effectiveness, especially pharmacological strategies based on a single therapeutic goal cannot effectively solve the complex mechanisms of obesity and its complications, and probiotic products are mainly based on Lactobacillus and Bifidobacteria. , failed to fully utilize the potential benefits of other bacteria that are naturally present in the human gut.
Using Holdemanella biformis strain CECT 9752 and its derivatives, it is used to prevent and treat energy homeostasis by regulating the enteroendocrine system, reducing inflammation, improving anti-inflammatory response, improving glucose metabolism and appetite regulation, reducing basal hyperglycemia, and improving glucose tolerance. Diseases related to glucose metabolism.
It significantly reduces inflammatory mediators, improves insulin sensitivity, improves glucose tolerance, reduces weight and body fat, and is suitable for a variety of diseases related to glucose metabolism disorders, providing a more effective alternative treatment plan.
Smart Images

Figure GDA0004421341650000171 
Figure GDA0004421341650000191 
Figure GDA0004421341650000201
Abstract
Description
Technical Field
[0001] The present invention relates to Holdemanella genus, Holdemanella biformis genus and H.biformis CECT9752 strain, cell components, metabolites and secretory molecules thereof, and compositions comprising the above products, and uses of the strains for preventing and / or treating changes in energy homeostasis and glucose metabolism. The present invention belongs to the field of therapeutic activity of pharmaceutical compositions or preparations, and also belongs to the field of food. Background Art
[0002] Obesity is currently a major global health challenge due to its high prevalence and comorbidities associated with altered energy homeostasis. These comorbidities include, for example, dyslipidemia, metabolic syndrome, diabetes, cardiovascular disease, hepatic steatosis or fatty liver, hypertension, retinopathy, and altered eating behavior. These pathologies, especially those involving altered glucose metabolism, such as diabetes, can also occur in non-obese subjects, although increased body weight is an important risk factor.
[0003] Obesity is characterized by weight and body mass gain, primarily caused by an imbalance between energy intake and expenditure.
[0004] The neuroendocrine system regulates energy balance through gut hormones, which are key to control intake and metabolism in different organs and tissues. Among the gut hormones, glucagon-like peptide 1 (GLP-1) and peptide YY (PYY), which are secreted by L cells mainly present in the distal areas of the intestine, stand out. These hormones not only have direct effects on distal organs (liver, adipose tissue) to control energy metabolism, but they also act as mediators in the central control of metabolism and eating habits through neural and endocrine pathways via the gut-brain axis. GLP-1 is a peptide that suppresses appetite and induces satiety at the level of the hypothalamus, regulates glucose metabolism by inducing insulin secretion in the pancreas, reducing glucagon synthesis and decreasing gastric emptying. In addition, GLP-1 contributes to the reduction of body weight, hepatic steatosis, and the risk of diabetes and cardiovascular diseases. PYY is more stable than GLP-1; likewise, it mainly causes satiety and regulates glucose metabolism by reducing gastric emptying, thus contributing to the reduction of intake and body weight. It also reduces excessive food consumption by activating pro-opiomelanocortin (POMC) and inhibiting neuropeptide Y (NPY) in the central nervous system.
[0005] The liver is an important organ that integrates endocrine, neural, and nutritional signals in order to store or mobilize nutrients according to energy requirements. This combined action makes the liver an important organ for maintaining energy homeostasis and blood glucose at physiological concentrations. Its metabolic activity is closely controlled by insulin and other metabolic hormones. In the presence of glucose, insulin stimulates glycolysis and lipogenesis but inhibits gluconeogenesis; in contrast, during prolonged fasting, hepatic gluconeogenesis is the main source of endogenous glucose production. The liver uses not only glucose as the main metabolic fuel, but also fatty acids. Hepatocytes acquire fatty acids from the blood, which are released from adipose tissue or absorbed from food in the gastrointestinal tract. Fatty acids are transferred to mitochondria by carnitine palmitoyltransferase 1 (CPT-1) for metabolism by acid β-oxidation to produce acetyl-CoA. Mitochondrial β-oxidation not only provides energy for hepatocytes, but also produces ketone bodies (β-hydroxybutyrate, acetoacetate, and acetone), which are exported to the circulation to provide energy for extrahepatic tissues. The intestine and liver are connected by the portal vein, which allows the transport of nutrients, hormones, and metabolites of the gut microbiota. Regulation of liver metabolism can also be regulated indirectly by the gut through the central nervous system (CNS). In response to food intake, signals are transmitted via vagal afferents to the nucleus tractus solitarius (NTS) in the brain.
[0006] Prevention and treatment strategies based on a low-calorie diet and increased physical activity are the first choice for managing obesity and its metabolic complications; however, their long-term effectiveness is often limited. For this reason, alternatives that support lifestyle modification are needed to improve their effectiveness. In addition, pharmacological strategies, including those based on GPL-1 receptor agonists, are limited in part because they continue to be consumed when used to treat chronic diseases. Moreover, their effectiveness is limited because they are based on a single therapeutic target without addressing the complexity of the mechanisms that lead to obesity and its complications.
[0007] In human observational studies, obesity and its comorbidities (type 2 diabetes, dyslipidemia, cardiovascular disease, fatty liver, metabolic syndrome, etc.) are associated with changes in the composition and function of the gut microbiota, suggesting that the gut microbiota may play an important role in these diseases. This hypothesis was confirmed by transferring the microbiota of diseased or healthy individuals to new subjects and observing that the latter acquired the phenotype of the donor. These experiments confirmed that the changes in the microbiota caused in part by a high-calorie diet led to the development of obesity and its metabolic complications. This evidence has led to the development of strategies for intervention in the intestinal ecosystem, such as the use of probiotics, as an alternative to improve the treatment and prevention of obesity. Due to their history of safe use in food, the products initially developed were based on bacterial strains belonging to the genera Lactobacillus and Bifidobacterium. However, it is now known that a higher proportion of other bacteria naturally present in the human gut, associated with a lean phenotype, may be more effective alternatives. Unlike pharmacological strategies, the advantage of using commensal intestinal bacteria is the ability to act through a variety of mechanisms of action, modulate endocrine and neural pathways that control energy balance, and a priori do not cause adverse effects. With regard to the possible beneficial properties of the Holdemanella genus and Holdemanella biformis species and strains thereof, there is no previous literature demonstrating their beneficial effects on the alterations and pathologies that are the subject of the present invention. SUMMARY OF THE INVENTION
[0009] The present invention relates to the Holdemanella genus, the Holdemanella biformis species and the H. biformis strain CECT 9752 and their cellular components, metabolites, molecules secreted by the bacteria, and compositions comprising the above products, and their use for preventing and / or treating alterations in energy homeostasis and glucose metabolism.
[0010] One of the beneficial effects of the bacterial subjects of the present invention and products derived therefrom is their ability to reduce cellular and humoral mediators of inflammation, which is associated with obesity and dysfunctions related to glucose metabolism (such as, but not limited to, insulin resistance, metabolic syndrome and diabetes).
[0011] As seen in the in vitro tests conducted by the inventors (Example 2 of the present specification), the bacteria within the scope of the present invention induce an anti-inflammatory response in peripheral blood mononuclear cells (PBMCs) because it increases the production of the anti-inflammatory cytokine IL-4 relative to the pro-inflammatory IFNγ, and reduces the level of classical monocytes (CD14++CD16-) in terms of the effects induced by lipopolysaccharide LPS, which is an inducer of inflammation in obesity (see Table 1). The above anti-inflammatory effects can improve insulin resistance and glucose intolerance caused by the pro-inflammatory state of obesity to a greater extent than other intestinal bacteria (see Example 2).
[0012] One of the essential aspects of the present invention is the ability of the Holdemanella species, in particular H. biformis and in particular the strain CECT 9752, to modulate the enteroendocrine system, thereby contributing to improved glucose metabolism and appetite regulation, which in the long term allows for a reduction in body weight and body fat. Among the most important results obtained in the in vivo tests (see Example 3), it is worth highlighting the ability of the strains included within the scope of the present invention to: (i) normalize the levels of peptide YY (PYY) and incretin GLP-1 in plasma (see Figure 2 a, 2b); (ii) reduce the basal hyperglycemia caused by a high-calorie diet (see Figure 1 a) and (iii) improve glucose tolerance during an oral glucose overload test (see Figure 1 b), in mice that developed an obese and prediabetic state when fed a diet high in energy content of saturated fat (45%) and sugar (20%). In addition, the bacteria restored the insulin signaling cascade and improved glucose uptake in the liver, as inferred from gene expression analyses performed in this organ (see Figure 3 and Figure 4 ).
[0013] The beneficial effects of these bacteria on maintaining or restoring energy homeostasis, especially glucose homeostasis, will be applicable to individuals with, or at risk for, hyperglycemia, hyperinsulinemia, glucose intolerance, insulin resistance, metabolic syndrome, type 2 diabetes, gestational diabetes, type 1 diabetes, pancreatic dysfunction, overweight, obesity, hormonal alterations, thyroiditis, liver dysfunction, hepatic steatosis, dyslipidemia, hypertriglyceridemia, cardiovascular disease, retinopathy, and altered dietary behavior.
[0014] Its administration as a food supplement or drug represents an important advance in the primary prevention of alterations in energy and glucose metabolism and the associated chronic pathologies, the prevalence of which has tripled in the last three decades due to excessive consumption of foods rich in fat and sugar, and which is one of the main causes of death in Western societies.
[0015] Therefore, in one aspect, the present invention relates to the H. biformis CECT 9752 strain, hereinafter referred to as "the strain of the present invention" or "strain CECT 9752" or "strain G59".
[0016] H. biformis was isolated from human feces. The strain was deposited at the Spanish Collection of Type Cultures (CECT, calle Catedrático Agustín Escardino, 9, 46980 Paterna, Valencia, Spain) by the Spanish National Research Council (CSIC) under the Budapest Treaty on November 5, 2018. The assigned deposit number is CECT 9752.
[0017] The scientific classification of the strain of the present invention is domain Bacteria; phylum Firmicutes; class Erysipelothrix; order Clostridium; family Salviae; genus Holdemanella; species Holdemanella biformis. Over time, the strain of the present invention has acquired different names, such as "Pseudobacterium biforme" (Eggerth 1935) Krasil'nikov 1949, Eubacterium biforme (Eggerth 1935) Prevot 1938 and "Bacteroides biformis" Eggerth 1935. It grows in minced meat medium (DSMZ medium 78) containing 0.1% Tween 80 at 37°C and anaerobic conditions.
[0018] Another aspect of the present invention relates to bacterial strains derived from strain H.biformis CECT 9752, wherein the abilities described throughout the present invention are maintained or improved. Derived microorganisms can be produced naturally or intentionally by mutagenesis methods known in the art, such as but not limited to growing the original microorganism in the presence of a mutagen or an agent causing stress, or by genetic engineering production intended to modify a specific gene. According to a preferred embodiment, the strain derived from strain H.biformis CECT 9752 is a genetically modified mutant. The terms "mutant strain" or "derivative strain" can be used interchangeably.
[0019] The strain H. biformis CECT 9752 or any mutant or derivative thereof may be used in any manner that exerts the described effect, for example, according to a preferred embodiment of the present invention, the strain H. biformis CECT 9752 is in the form of living cells (cultivable or non-cultivable), or according to another preferred embodiment of the present invention, the strain is in the form of non-living cells ("dead" cells inactivated by any technique known in the art, such as but not limited to heating, freezing or ultraviolet radiation).
[0020] Another aspect of the present invention relates to cellular components, metabolites, secreted molecules or any combination thereof obtained from the strains of the present invention or from a combination of microorganisms comprising at least one strain of the present invention.
[0021] The cell components of bacteria can include cell wall components (such as but not limited to peptidoglycan), nucleic acids, membrane components or other components, such as proteins, lipids and carbohydrates and combinations thereof, such as lipoproteins, glycolipids or glycoproteins. Metabolites include any molecule produced or modified by the metabolic activity of bacteria during its growth, in a technical process (such as but not limited to a food or drug manufacturing process), in a product storage process or in a gastrointestinal transport process. Examples of these metabolites are but not limited to organic and inorganic acids, proteins, peptides, amino acids, enzymes, lipids, carbohydrates, lipoproteins, glycolipids, glycoproteins, vitamins, salts, metals or nucleic acids. Secreted molecules include any molecule exported or released to the outside by bacteria during its growth, its use in a technical process (such as, food or drug manufacturing), product storage or gastrointestinal transport. Examples of these molecules are but not limited to organic and inorganic acids, proteins, peptides, amino acids, enzymes, lipids, carbohydrates, lipoproteins, glycolipids, glycoproteins, vitamins, salts, metals or nucleic acids.
[0022] Another aspect of the present invention relates to a composition, hereinafter referred to as "the composition of the present invention", comprising the strain of the present invention and / or cellular components, metabolites, secreted molecules of the strain of the present invention or any combination thereof.
[0023] A composition defined in a general manner is a set of components consisting of at least the strain of the present invention in any concentration; or at least cellular components, metabolites, secreted molecules of the strain of the present invention or any combination thereof; or a combination thereof.
[0024] In a preferred embodiment, the composition of the present invention has 10 3 Up to 10 14 The concentration of the strain of the present invention is 100 colony forming units (cfu).
[0025] In another specific embodiment, the composition of the present invention may further comprise at least one other additional microorganism of the same or different genus, species or strain of the present invention and / or its cellular components, metabolites or secreted molecules, or any combination thereof. For example, but not limited to, the additional microorganism that may be part of the composition is selected from at least one of the following groups:
[0026] - at least one strain of another species of the genus Holdemanella or H. biformis;
[0027] - at least one strain of another species of the genus Bacteroides or B. uniformis;
[0028] - at least one strain of the genus Phascolarctobacterium or the species P. faecium;
[0029] - at least one strain of the genus Christensenella and the species C. minuta;
[0030] - at least one lactic acid bacterium or Bifidobacterium of human, food or environmental origin. The lactic acid bacterium is selected from the list of bacteria including but not limited to Bifidobacterium, Lactobacillus, Lactococcus, Enterococcus, Propionibacterium, Leuconostoc, Weissella, Pediococcus or Streptococcus;
[0031] Bacteria of the genus Bifidobacterium, Lactobacillus, Lactococcus, Enterococcus, Propionibacterium, Leuconostoc, Weissella, Pediococcus or Streptococcus;
[0032] - a strain of at least one other phylogenetic group, genus or species of prokaryotes of human, food or environmental origin, such as but not limited to Archaea, Bacteroidetes, Bacteroidetes, Proteobacteria, Actinobacteria, Verrucomicrobia, Fusobacteria, Methanobacteria, Spirochaetes, Fibrobacterium, Deferribacterium, Deinococcus, Thermus, Cyanobacteria, Methanobrevibacterium, Peptostreptococcus, Ruminococcus, Coprococcus, Subdolingranulum, Dorea, Bulleidia, Anaerofustis, Gemella, Roseburia, Catenibacterium, Dialister, Anaerotruncus, Staphylococcus, Micrococcus, Propionibacterium, Enterobacteriaceae, Faecalibacterium, Bacteroides, Parabacteroides, Prevotella, Eubacterium, Akkermansia, Bacillus, Butyrivibacterium or Fusobacterium;
[0033] - At least one fungus or yeast strain, such as but not limited to one belonging to the genus Saccharomyces, Candida, Pichia, Debaryomyces, Torulina, Aspergillus, Rhizopus, Mucor or Penicillium.
[0034] The additional microorganisms can be strains from the same species or different species or from a taxonomic group of microorganisms corresponding to the strains of the present invention. The cells comprising the composition can be non-viable or viable and in any stage of development or growth (latent, exponential, stationary, etc.), regardless of the morphology they have. In a specific embodiment, the additional microorganisms include at least one enterobacterium or a lactic acid bacterium, particularly a human enterobacterium.
[0035] Optionally, in another specific embodiment, the composition of the present invention may further comprise at least one biologically active ingredient (active substance, active ingredient or therapeutic agent), such as other food ingredients, plant products and / or drugs.
[0036] The term "bioactive ingredient" refers to a compound with biological activity within the scope of the patent application that can enhance or supplement the activity of strain CECT 9752, including food ingredients or components (for example, but not limited to: polyunsaturated fatty acids, conjugated linoleic acid, prebiotics, fiber, guar gum, glucomannan, chitosan, copper picolinate, calcium, etc.), other probiotics, plants, plant extracts or components and drugs.
[0037] In a particular embodiment, the composition of the invention is a pharmaceutical composition. A pharmaceutical composition is a set of components consisting of at least any concentration of the strain of the invention; or at least the cellular components, metabolites, secreted molecules or any combination thereof of the strain of the invention, which has at least one application in improving the physical, physiological or mental health of a subject, meaning that their overall health is improved or the risk of disease is reduced. The pharmaceutical composition may be a drug.
[0038] The term "drug" has a more limited meaning than the meaning of "pharmaceutical composition" defined in the present invention, since "drug" necessarily implies a preventive or therapeutic effect. The drugs to which the present invention relates may be for human or veterinary use. "Human drug" refers to any substance or combination of substances that has therapeutic or preventive properties for human diseases, or that can be used or administered to humans to restore, correct or modify a physiological function, to exert a pharmacological, immunological or metabolic effect, or to establish a medical diagnosis. "Veterinary drug" refers to a substance or combination of substances that has therapeutic or preventive properties for animal diseases, or that can be administered to animals to restore, correct or modify their physiological functions, to exert a pharmacological, immunological or metabolic effect, or to establish a veterinary diagnosis. "Veterinary drugs" will also be considered as "medicated feed premixes" to be incorporated into feed.
[0039] In addition to the requirement for therapeutic efficacy, the pharmaceutical composition may require the use of other therapeutic agents, there may be other fundamental reasons that force or recommend the use of a combination of the compound of the present invention and a biologically active ingredient to a large extent, wherein the biologically active ingredient has appropriate activity to constitute a drug. The compound of the present invention obviously refers to the strain of the present invention, or a strain derived therefrom, or a cellular component, metabolite, secreted molecule or any combination thereof obtained from the strain of the present invention.
[0040] In certain embodiments, the pharmaceutical composition further comprises at least a pharmaceutically acceptable carrier and / or excipient.
[0041] "Carrier" is preferably an inert substance. The function of the carrier is to facilitate the incorporation of other compounds, allow better dosage and administration or give consistency and shape to the pharmaceutical composition. Therefore, the carrier is a substance used in the drug to dilute any component of the pharmaceutical composition of the present invention to a certain volume or weight; or, even without diluting the component, it can allow better dosage and administration or give consistency and shape to the drug. When the presentation form is a liquid, the pharmaceutically acceptable carrier is a diluent.
[0042] The term "excipient" refers to a substance that helps the absorption of any component of the composition of the invention, stabilizes said component or helps prepare the pharmaceutical composition, in the sense of giving it consistency or providing it to make it more pleasant. Thus, an excipient may have the function of holding the components together (for example starch, sugar or cellulose), the function of sweetening, the function of coloring, the function of protecting the drug (for example isolating it from air and / or moisture), the function of filling the presentation form of tablets, capsules or any other form (for example calcium hydrogen phosphate), the function of disintegration, in order to facilitate the dissolution and absorption of the ingredients in the intestine, without excluding other types of excipients not mentioned herein. Thus, the term "excipient" is defined as a material, included in the galenic formulation, added to the active ingredient or its combination to allow its preparation and stability, to modify its organoleptic properties or to determine the physicochemical properties of the pharmaceutical composition and its bioavailability. A "pharmaceutically acceptable" excipient must take into account the activity of the compounds of the pharmaceutical composition, in other words, it is compatible with said components.
[0043] Furthermore, as will be understood by those skilled in the art, excipients and carriers must be pharmacologically acceptable, in other words, the excipients and carriers are permitted and evaluated so as not to cause harm to the organism to which they are administered.
[0044] Pharmaceutical composition or medicine can exist with any clinically allowed administration form and therapeutically effective amount.For example, it can be suitable for oral, sublingual, nasal, intrathecal, bronchial, lymphatic, rectal, percutaneous, suction or parenteral administration, preferably suitable for oral administration.Pharmaceutical composition of the present invention can be made into solid, semisolid, liquid or gaseous form, such as tablet, capsule, powder, granule, ointment, solution, suppository, injection, inhalant, gel, microsphere or aerosol.The form suitable for oral administration is selected from including but not limited to the list of drops, syrup, cold tea, elixir, suspension, temporary suspension, drinkable vial, tablet, capsule, granule, pouch, caplet, pill, pill, lozenge or lyophilized agent form.In a specific embodiment, composition of the present invention exists with the form suitable for oral, sublingual, nasal, bronchial, lymphatic, rectal, percutaneous, suction or parenteral administration.
[0045] In a more specific embodiment, the composition of the present invention is in a form suitable for oral administration. A form suitable for oral administration refers to a physical state that allows it to be administered orally. The form suitable for oral administration is selected from a list including but not limited to drops, syrups, herbal teas, elixirs, suspensions, extemporaneous suspensions, drinkable vials, tablets, capsules, granules, sachets, caplets, pills, pellets, lozenges or lyophilized forms.
[0046] "Galenical form" or "pharmaceutical form" is the disposition in which the active ingredients and excipients are adapted to constitute a drug. It is defined by the combination of the form in which the pharmaceutical composition is presented by the manufacturer and the form in which it is administered.
[0047] In the present invention, the term "therapeutically effective amount" refers to an amount of a component of a pharmaceutical composition that is sufficient to produce the prevention and / or treatment of a disease or pathological condition of interest in a mammal, preferably a human, as defined below, when administered to a mammal, preferably a human. The therapeutically effective amount will vary depending on, for example, the activity of the strain of the present invention; the cellular components, metabolites, secreted molecules, or any combination thereof in any form; the therapeutically effective amount will also vary depending on the metabolic stability and duration of action of the compound; the patient's age, weight, general health, sex, and diet; the mode and time of administration; the excretion rate, drug combination; the severity of a particular disease or pathological condition; and the patient being treated, but this can be determined by a person skilled in the art based on his or her own knowledge and description.
[0048] Another aspect of the present invention relates to the use of the strain of the present invention, or a component derived therefrom, or the composition of the present invention for the manufacture of a medicament.
[0049] Another aspect of the invention relates to strain CECT 9752, cellular components, metabolites, secreted molecules or any combination thereof obtained from the strain of the invention or the composition of the invention for use as a medicament. The term "medicament" has been defined previously and it applies to aspects of the invention.
[0050] In another aspect, the present invention relates to the use of a Holdemanella bacterium or a bacterium derived therefrom, a cellular component, a metabolite, a secreted molecule or any combination thereof derived from a Holdemanella bacterium, or a composition comprising a Holdemanella bacterium for preventing and / or treating a disease associated with altered glucose metabolism selected from glucose intolerance, insulin resistance, metabolic syndrome, type 2 diabetes, gestational diabetes, type 1 diabetes, pancreatic dysfunction, overweight, obesity, hormonal changes, thyroiditis, liver dysfunction, hepatic steatosis, dyslipidemia, hypertriglyceridemia, cardiovascular disease and retinopathy.
[0051] In a specific embodiment, the Holdemanella bacterium is a H. biformis species, in particular the H. biformis strain with the deposit number CECT9752.
[0052] In the present invention, the term "treatment" refers to counteracting the effects of a disease or pathological condition of interest in a subject (preferably a mammal, more preferably a human being), including:
[0053] (i) inhibiting a disease or pathological condition, in other words, preventing its development;
[0054] (ii) alleviate the disease or pathological condition, in other words, cause amelioration of the disease or pathological condition or its symptoms;
[0055] (iii) Stabilization of a disease or pathological condition.
[0056] In the present invention, the term "prevention" refers to preventing the occurrence of a disease, in other words, preventing a disease or a pathological condition from occurring in a subject (preferably a mammal, more preferably a human), especially when the subject has a predisposition to the pathological condition.
[0057] In the present invention, "diseases associated with altered glucose metabolism" are understood as all those diseases in which an incorrect use of glucose by cells, organs or tissues can arise in a primary or secondary manner, including hyperglycemia, hyperinsulinemia, glucose intolerance, insulin resistance, metabolic syndrome, type 2 diabetes, gestational diabetes, type 1 diabetes, pancreatic dysfunction, overweight, obesity, hormonal changes, thyroiditis, liver dysfunction, hepatic steatosis, dyslipidemia, hypertriglyceridemia, cardiovascular disease and retinopathy.
[0058] In the present invention, "glucose intolerance" is understood as a change that occurs due to lack of insulin production or resistance, in which the pancreas does not produce enough insulin to metabolize blood sugar, resulting in high blood sugar levels. However, even if the blood sugar level is higher than normal, it cannot be classified as diabetes. This state is considered "pre-diabetes."
[0059] In the present invention, "insulin resistance" is understood as a condition in which the response of tissues to the action of insulin is reduced, which makes it difficult for them to have circulating glucose; in particular the liver, skeletal muscle, adipose tissue and brain. This change, combined with insufficient insulin production by the pancreas, may lead to the development of type 2 diabetes over time. Resistance to insulin is also called insulin resistance.
[0060] In the present invention, "metabolic syndrome" is understood to be a disease comprising a group of conditions that put an individual at risk for heart disease and type 2 diabetes. Examples of these conditions include, but are not limited to, arterial hypertension, high blood sugar, high triglyceride blood levels, low blood levels of high-density lipoproteins and excess fat around the waist.
[0061] In the present invention, "type 2 diabetes" is understood to be a disease characterized by high levels of glucose in the blood, either because the pancreas does not produce enough insulin or because the cells are insensitive to insulin and cannot use it. Insulin is a hormone that helps glucose enter cells to provide energy for the cells. Over time, high blood sugar levels can cause serious problems with the heart, eyes, kidneys, nerves, gums and teeth. When diabetes develops during pregnancy, it is called gestational diabetes.
[0062] In a specific embodiment, the present invention relates to a bacterium of the genus Holdemanella or a bacterium derived therefrom, a cellular component, a metabolite, a secreted molecule or any combination thereof derived from a bacterium of the genus Holdemanella, or a composition comprising a bacterium of the genus Holdemanella for use as an adjuvant for the treatment of any of the diseases mentioned in the preceding paragraphs.
[0063] In the present invention, "adjuvant" is understood to contribute to:
[0064] - Improve the effectiveness or efficiency of other drugs for the treatment of conditions associated with altered glucose metabolism, including hyperglycemia, hyperinsulinemia, glucose intolerance, insulin resistance, metabolic syndrome, type 2 diabetes, gestational diabetes, type 1 diabetes, pancreatic dysfunction, overweight, obesity, hormonal changes, thyroiditis, liver dysfunction, hepatic steatosis, dyslipidemia, hypertriglyceridemia, cardiovascular disease, and retinopathy, and / or
[0065] - Reducing the frequency of application or enhancing its efficacy by administering preparations of the strains of the invention having a complementary mechanism of action.
[0066] In another specific embodiment, the treatment of diabetes 2 is based on incretins. In the present invention, "incretins" are understood to be a series of hormones that are produced in the intestine in response to food intake and regulate it, as well as glucose metabolism. One of its most important effects is to stimulate the pancreas to secrete insulin and lower blood sugar levels. The two main incretins are gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1).
[0067] In a further aspect, the present invention relates to a bacterium of the genus Holdemanella or a bacterium derived therefrom, a cellular component, a metabolite, a secreted molecule or any combination thereof derived from a bacterium of the genus Holdemanella, or a composition comprising a bacterium of the genus Holdemanella for use in preparing a food. The term medicament has been previously defined in this specification and applies to aspects of the present invention.
[0068] In a specific embodiment of the use of the present invention, the bacterium is a genetically modified mutant.
[0069] In another specific embodiment of the use according to the invention, the bacteria are in the form of living cells or non-living cells.
[0070] In a further specific embodiment of the use according to the invention, the composition additionally comprises at least one biologically active ingredient.
[0071] In a further specific embodiment of the use according to the invention, the composition further comprises at least one microorganism other than a bacterium of the genus Holdemanella, in particular H. biformis, more particularly H. biformis CECT 9752. In a more specific embodiment, the microorganism other than a bacterium of the genus Holdemanella is a human bacterium or a lactic acid bacterium.
[0072] In another specific embodiment of the use according to the invention, the composition is a pharmaceutical composition. In a more specific embodiment, the composition further comprises at least one pharmaceutically acceptable carrier and / or excipient.
[0073] In another specific embodiment of the use according to the invention, the composition is in a form suitable for oral, sublingual, nasal, bronchial, lymphatic, rectal, transdermal, inhalation or parenteral administration.
[0074] In another specific embodiment of the use of the present invention, the composition has 10 3 Up to 10 14 The concentration of the strain is expressed as colony forming units (cfu).
[0075] In another specific embodiment of the use according to the present invention, the bacterium of the genus Holdemanella is a species of H. biformis, in particular the H. biformis strain with the deposit number CECT 9752.
[0076] Throughout the specification and claims, the word "comprising" and its variants are not intended to exclude other technical features, additives, components or steps. For those skilled in the art, other objects, advantages and features of the present invention can be partially derived from the description and embodiments of the present invention. The following examples and drawings are provided for illustration only and are not intended to limit the present invention. Sequence Listing <110> Spanish Higher Council for Scientific Research <120> Holdemanella sp. bacteria and their uses <130> PCT1641.1417 <150> ES P201831282 <151> 2018-12-26 <160> 27 <170> PatentIn version 3.5 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Primer 27F <400> 1 agagtttgat cctggctcag 20 <210> 2 <211> 17 <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Primer 1401r <400> 2 cggtgtgtac aagaccc 17 <210> 3 <211> 1268 <212> DNA <213> Holdemanella biformis <400> 3 cttcatgaag tcgggttgca gacttcaatc cgaactgaga cgtcctttat gagattcgct 60 tgccttcaca ggcttgccgc tctttgtaga cgccattgta gtacgtgtgt agcccaggcc 120 ataaggggca tgatgatttg acgtcatccc caccttcctc cggtttatca ccggcagtct 180 gatatgagtc ctcaactcaa tgttagtaac atatcacaag ggttgcgctc gttgcgggac 240 ttaacccaac atctcacgac acgagctgac gacaaccatg caccacctgt ctccttgata 300 acctcggata tatctctata cctctgcaag ggatgtcaag gcctggtaag gttcttcgcg 360 ttgcttcgaa ttaaaccaca tactccaccg cttgtgcggg cccccgtcaa ttcctttgag 420 tttcacactt gcgtgcatac tccccaggcg gagaacttat tgcgttaact gcggcactga 480 gttattcccc caacacctag ttctcatcgt ttacggcgtg gactactagg gtatctaatc 540 ctatttgctc cccacgcttt cgtgcttcag tgtcagaatc cagaccagac ggccgccttc 600 gccaccggtg ttcttccata tatctacgca ttttaccgct acacatggag ttccgccgtc 660 ctcttctgtt ctctagctga tcagtttcca gagcaagtac gggttgagcc catacctttt 720 actccagact tgatctgcca cctacgcacc ctttacgccc aatcattccg gataacgctc 780 gccacctacg tattaccgcg gctgctggca cgtagttagc cgtgactttc tggtaagata 840 ccatcactca ctcatcattc cctatgagtg ccgtttttct cttacaacag agctttacga 900 tccgaagacc ttcctcactc acgcggcatt gctcgttcag ggttcccccc attgacgaaa 960 attccctact gctgcctccc gtaggagttt gggccgtgtc tcagtcccaa tgtggccgtc 1020 cgccctctca ggccggctat gcatcgtcgc cttggtgggc cgttacctca ccaactagct 1080 aatgcaccgc aggtccatcc atgttcatgg ccttagccac tttaatagca gtcaaatgct 1140 tgtctgctac ctatccggtt ttagcatccg tttccagaag ttatcccggg cacatgggca 1200 ggttacctac gtgttactca cccgttcgcc actagattta ggaaagcaag ctttccttcc 1260 tctcgttc 1268 <210> 4 <211> 21 <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Forward primer G6Pc <400> 4 ttaccaagac tcccaggact g 21 <210> 5 <211> 21 <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Reverse primer G6Pc <400> 5 gagctgttgc tgtagtagtc g 21 <210> 6 <211> twenty one <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Forward primer GcK <400> 6 atgtgaggtc ggcatgattg t 21 <210> 7 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Reverse primer GcK <400> 7 ccttccacca gctccacatt 20 <210> 8 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Forward primer PCK1 <400> 8 agcctttggt caacaactgg 20 <210> 9 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Reverse primer1 PCK <400> 9 tgccttcggg gttagttatg 20 <210> 10 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Forward primer LpL <400> 10 tgaaagccgg agagactcag 20 <210> 11 <211> twenty two <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Reverse primer LpL <400> 11 agtgtcagcc agacttcttc ag 22 <210> 12 <211> twenty two <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Forward primer ACC <400> 12 taatgggctg cttctgtgac tc 22 <210> 13 <211> twenty two <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Reverse primer ACC <400> 13 ctcaatatcg ccatcagtct tg 22 <210> 14 <211> twenty one <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Forward primer FAS <400> 14 ggaggtggtg atagccggta t 21 <210> 15 <211> twenty one <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Reverse primer FAS <400> 15 tgggtaatcc atagagccca g 21 <210> 16 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Forward primer HSL <400> 16 atgccactca cctctgatcc 20 <210> 17 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Reverse primer HSL <400> 17 ctgtcctgtc cttcccgtag 20 <210> 18 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Forward primer CPT1a <400> 18 tttgaatcgg ctcctaatgg 20 <210> 19 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Reverse primer CPT1a <400> 19 cccaagtatc cacagggtca 20 <210> 20 <211> twenty one <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Forward primer GLP-1R <400> 20 ggcgtcaact ttcttatctt c 21 <210> twenty one <211> twenty one <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Reverse primer GLP-1R <400> twenty one caaagatgac ttcatgtgtc c 21 <210> twenty two <211> 20 <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Forward primer peripherin <400> twenty two atctcagtgc cggttcattc 20 <210> twenty three <211> 20 <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Reverse primer peripherin <400> twenty three gggccaagct taggaatagg 20 <210> twenty four <211> 25 <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Forward primer proglucagon <400> twenty four caaaccaaga tcactgacaa gaaat 25 <210> 25 <211> twenty two <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Reverse primer proglucagon <400> 25 gggttacaca atgctagagg ga 22 <210> 26 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Forward primer PYY <400> 26 cttcacagac gacagcgaca 20 <210> 27 <211> twenty one <212> DNA <213> Artificial Sequence <220> <221> <222> <223> Reverse primer PYY <400> 27 gggaaatgaa cacacacagc c 21 BRIEF DESCRIPTION OF THE DRAWINGS
[0078] Figure 1 :The strain H.biformis CECT 9752 (1x10 8 cfu / day) administered to obese C57BL / 6 mice (n=10 / group) for 14 weeks on basal blood glucose and glucose tolerance. (a) Fasting blood glucose levels (mg / dl) at weeks 8 and 10. (b) Glucose tolerance test, blood glucose was measured 15, 30, 60 and 120 minutes after oral glucose overload (2 g / Kg). The area under the curve (AUC) of the glucose tolerance test results is shown. Data are expressed as mean and standard error. Statistically significant differences (p<0.05) were established by applying one-way ANOVA followed by Tukey's test. CD, control diet; HFHSD, high fat diet; HFHSD+H.biformis, high fat diet+H.biformis (1x10 8 cfu / day).
[0079] Figure 2 :The strain H.biformis CECT 9752 (1x10 8 cfu / day) administered to obese C57BL / 6 mice (n=10 / group) for 14 weeks on the levels of GLP1 and PYY in plasma. (a) pg / ml levels of GLP-1 (glucagon-like peptide) and (b) PYY (peptide YY). Data are expressed as mean and standard error. Statistically significant differences (p<0.05) were established by applying one-way ANOVA followed by Tukey's test. CD, control diet; HFHSD, high-fat diet.
[0080] Figure 3 :The strain H.biformis CECT 9752 (1x10 8cfu / day) administered to obese C57BL / 6 mice (n=10 / group) for 14 weeks on the enzymatic levels of hepatic energy metabolism. Relative expression of genes: glucokinase (GcK), glucose-6-phosphatase catalytic unit (G6Pc), phosphoenolpyruvate carboxylase 1 (PcK1), lipoprotein lipase (LpL), acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), hormone-sensitive lipase (HSL), and carnitine palmitoyltransferase (Cpt1a). Statistically significant differences were established by applying one-way ANOVA and Tukey's test (p<0.05) (a and b). CD, control diet; HFHSD, high-fat diet.
[0081] Figure 4 :The strain H.biformis CECT 9752 (1x10 8 cfu / day) administered to obese C57BL / 6 mice (n=10 / group) for 14 weeks affected the expression levels of (a) peripherin and (b) GLP-1 receptor and proglucagon (c) in the ileum. Statistically significant differences (p<0.05) were established by applying one-way ANOVA followed by Tukey's test. CD, control diet; HFHSD, high-fat diet. Example
[0082] Next, the present invention will be explained by experiments conducted by the inventors, which demonstrate the effectiveness of the product of the present invention.
[0083] Example 1. Isolation and identification of Holdemanella biformis.
[0084] Different intestinal bacteria were isolated from the feces of healthy volunteers. 1.25 g of feces was used and diluted in 10 mM phosphate buffer containing 0.05% cysteine (1:10 dilution), wherein the NaCl concentration was 130 mM (PBS) and homogenized in a Lab-Blender Stomacher 400 (Seward Medical, London, 35 UK). The dilution was inoculated in 37.5 ml of intestinal bacteria culture medium (IBM), whose composition was based on the culture medium recommended in previous publications (Gibson, GR, et al., Appl. Environ. Microbiol., 54 (1 1): 2750-5, 1988; Lesmes, U et al., J. Agric. Food Chem., 56: 5415-5421, 2008), with some modifications designed by the inventors:
[0085] -Main Ingredients: Distilled water (1600 ml), peptone water (4 g), NaHCO3 (4 g), CaCl2 (0.02 g), pectin (4 g), xylan (4 g), wheat bran extract (4 g), arabinogalactan (2 g), gum arabic (2 g), starch (10 g), casein (6 g), inulin (2 g), NaCl (0.2 g). Autoclave at 121°C for 60 minutes and then cool overnight.
[0086] -Mucin solution : Mucin (8 g), distilled water (200 ml). Autoclave for 20 minutes.
[0087] -Salt and vitamins : Distilled water (100 ml), K2HPO4 (0.08 g), KH2PO4 (0.08 g), MgSO4 (0.02 g), hemin (0.01 g) and menadione (0.002 g).
[0088] -Cysteine solution : L-cysteine-HCl (1 g), distilled water (100 ml).
[0089] The salt and vitamin mixture was mixed with the cysteine solution and 6 M KOH was added until the final solution turned translucent brown and sterilized by filtration.
[0090] The final IBM was obtained by mixing the main ingredients, mucin solution, salts and vitamins and cysteine solution to a volume of 2 L under sterile conditions.
[0091] 50 ml of feces diluted in the IBM medium prepared by the inventors were fermented in an anaerobic chamber (Whitley DG250 Workstation, Don Whitley Scientific) for 24 hours with stirring, maintaining the pH value between 6.9 and 7.0.
[0092] The IBM medium fermented for 24 hours was filtered (through a pore size of 0.22 μm) and used as a supplement to "Fastidious Anaerobe Agar" (FAA) medium agar plates containing 0.5% defibrinated blood, which were inoculated with serial dilutions of fermented feces (0.1 ml of inoculum for each serial dilution in each plate). This IBM fermentation medium supplement contains substrates produced by the intestinal microbiota, and this medium is rich in nutrients present in the intestinal ecosystem, allowing for better recovery of native bacteria under laboratory conditions. The inoculated plates were incubated at 37°C for 72 hours in an anaerobic chamber.
[0093] Holdemanella biformis CECT 9752 was isolated from the colonies grown on the plate after 72 hours. It was identified by sequencing the 16S rRNA gene (1.26 Kb) using primers 27f (5'-AGAGTTTGATCCTGGCTCAG-3' (SEQ ID NO: 1)) and 1401r (5'-CGGTTGGTTACAAGACCC-3' (SEQ ID NO: 2). The reaction after DNA amplification was purified using Illustra GFX PCR DNA and gel band purification kit (GE Healthcare) and sequenced by Sanger technology in an ABI 3730XL sequencer (Stabvida-Caparica-Portugal). The identification of the isolated strain (G59) with the Holdemanella biformis strain DSM3989 (partial sequence, 16S ribosomal RNA) obtained 98% identity by comparing the sequences obtained with the NCBI database and the BLASTn algorithm.
[0094] The 16S sequence (SEQ ID NO: 3) was used for identification by the Blastn algorithm and sequenced using oligonucleotides 27F and 1401r:
[0095] CTTCATGAAGTCGGGTTGCAGACTTCAATCCGAACTGAGACGTCCTTTATGAGATTCGCTTGCCTCACAGGCTTGCCGCTCTTTGTAGACGCCA
[0096] TTGTAGTACGTGTGTAGCCCAGGCCATAAGGGGCATGATGATTTGAC
[0097] GTCATCCCCACCTTCCTCCGGGTTTATCACCGGCAGTCTGATATGAGTC
[0098] CTCAACTCAATGTTAGTAACATATCACAAGGGTTGCGCTCGTTGCGG
[0099] GACTTAACCCAACATCTCACGACACGAGCTGACGACAACCATGCACC
[0100] ACCTGTCTCCTTGATAACCTCGGATATATCTCTATACCTCTGCAAGGGA
[0101] TGTCAAGGCCTGGTAAGGTTCTTCGCGTTGCTTCGAATTAAACCACAT
[0102] ACTCCACCGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTTCACAC
[0103] TTGCGTGCATACTCCCCAGGCGGAGAACTTATTGCGTTAACTGCGGC
[0104] ACTGAGTTATTCCCCCAACACCTAGTTCTCATCGTTTACGGCGTGGAC
[0105] TACTAGGGTATCTAATCCTATTTGCTCCCCACGCTTTCGTGCTTCAGTG
[0106] TCAGAATCCAGACCAGACGGCCGCCTTCGCCACCGGTGTTCTTCCAT
[0107] ATATCTACGCATTTTACCGCTACACATGGAGTTCCGCCGTCCTCTTCTG
[0108] TTCTCTAGCTGATCAGTTTCCAGAGCAAGTACGGGTTGAGCCCATAC
[0109] CTTTTACTCCAGACTTGATCTGCCACCTACGCACCCTTTACGCCCAAT
[0110] CATTCCGGATAACGCTCGCCACCTACGTATTACCGCGGCTGCTGGCAC
[0111] GTAGTTAGCCGTGACTTTCTGGTAAGATACCATCACTCACTCATCATT
[0112] CCCTATGAGTGCCGTTTTTCTCTTACAACAGAGCTTTACGATCCGAAG
[0113] ACCTTCCTCACTCACGCGGCATTGCTCGTTCAGGGTTCCCCCCATTGA
[0114] CGAAAATTCCCTACTGCTGCCTCCCGTAGGAGTTTGGGCCGTGTCTC
[0115] AGTCCCAATGTGGCCGTCCGCCCTCTCAGGCCGGCTATGCATCGTCG
[0116] CCTTGGTGGGCCGTTACCTCACCAACTAGCTAATGCACCGCAGGTCC
[0117] ATCCATGTTCATGGCCTTAGCCACTTTAATAGCAGTCAAATGCTTGTCTGCTACCTATCCGGTTTTAGCATCCGTTTCCAGAAGTTATCCCGGGCACATGGGCAGGTTACCTACGTGTTACTCACCCGTTCGCCACTAGATTTAGGAAAGCAAGCTTTCCTTCCTCTCGTTC
[0118] The specific growth of this strain was optimized for future analyses using the methods recommended by the DSMZ Culture Collection.The culture medium consisted of minced meat (minced meat medium) (DSMZ medium 78) and 0.1% Tween 80.
[0119] Example 2. Selection of H. biformis based on its ability to modulate inflammation in vitro.
[0120] In vitro assays were performed to comparatively evaluate the immunomodulatory properties of a collection of bacterial isolates in order to select bacteria that were able to induce the greatest anti-inflammatory response in classical monocytes and, therefore, were of potential therapeutic interest for the treatment of inflammation and alterations in glucose metabolism associated with obesity. To this end, cell suspensions of the different bacteria were used as stimuli and the number of peripheral blood mononuclear cells (PBMCs) and classical monocytes as well as the levels of the anti-inflammatory cytokine IL-4 relative to the pro-inflammatory cytokine IFNγ were measured by flow cytometry.
[0121] - PBMC culture and stimulation
[0122] Peripheral blood mononuclear cells (PBMC) were isolated from whole blood of healthy volunteers using a Ficoll gradient (Ficoll Paque-Plus 17-1440-02, Bioscience). After treating them with a solution that lyses red blood cells (red blood cell lysis buffer, RBC, Miltenyi Biotec., Spain), they were resuspended in RPMI 1640 culture medium (Gibco, Barcelona, Spain) and supplemented with 10% fetal bovine serum (Gibco, Barcelona, Spain), streptomycin (100 μg / ml, Sigma), penicillin (100 U / ml, Sigma) and L-glutamine (Sigma). For the experiment, PBMC were incubated at 37°C, 5% CO2 in a 24-well flat-bottom polystyrene plate (Corning, Madrid, Spain) at a concentration of 106 / ml. The concentration used was 10 7 cfu / ml of live bacterial suspension was used as a stimulant. Purified lipopolysaccharide (LPS) from Salmonella enterica serotype Typhimurium (SigmaChemical Co, Madrid, Spain) was used as a positive control at a concentration of 1 μg / ml, and untreated PBMC samples were used as negative controls. At 37°C, 5% CO2, the stimulation time was 24 hours. After this period of time, cells were collected and centrifuged, and the cell pellet was separated from the supernatant. Each type of stimulation was measured in triplicate in 3 independent experiments. The culture supernatant was graded and stored in equal parts at -80°C.
[0123] - Characterization of the immunomodulatory properties of isolated bacterial strains on PBMCs by flow cytometry
[0124] Stimulated PBMCs were analyzed by flow cytometry to determine the level of classical proinflammatory monocytes, using markers CD14 and CD16. In addition, the levels of proinflammatory cytokines IFNγ and anti-inflammatory cytokines IL-4 in monocytes were also assessed. To this end, cells were permeabilized and fixed (Fixation / Permeabilization Solution Kit, BD-Bioscience) and resuspended with FACS solution (PBS1X+BSA 0.2%). Marker levels were measured using BD LSRFortessa.
[0125] From the isolated bacterial collection, the Holdemanella biformis CECT 9752 strain of the present invention was the strain that induced the most significant immunomodulatory effects, inducing higher production of the anti-inflammatory cytokine IL-4 relative to pro-inflammatory IFNγ (higher IL-4 / IFNγ), and reducing classical pro-inflammatory monocytes (CD14++CD16-) relative to untreated and LPS-treated cells (Table 1). This strain was selected to evaluate its ability to prevent changes in glucose metabolism in an obese animal model (Example 3).
[0126] Table 1: In vitro characterization of the immunomodulatory properties of bacterial isolates on PBMCs. Results are expressed as the mean and standard error (in parentheses) of the relative levels of classical monocytes and the IL-4 / IFNγ ratio measured by flow cytometry. Significant differences (P < 0.05) between groups were determined by one-way ANOVA followed by Tukey's test. Different letters indicate significant differences between experimental groups.
[0127]
[0128] Example 3. Characterization of the role of H. biformis in regulating energy and glucose metabolism in an animal model of obesity
[0129] Development and sampling of animal models of obesity
[0130] Adult male C57BL / 6 mice (6-8 weeks, Charles River, Les Oncins, France) were kept under controlled temperature (23°C), relative humidity (40-50%) and 12-h light / dark cycle and fed a high-calorie diet rich in fat (45% Kcal) and sucrose (17% Kcal) (HFHSD; D12451, Research Diets, Brogaarden, Denmark) or a control diet with standard fat content and no sucrose (CD, 10% Kcal from fat; D12450K, Research Diets, Brogaarden, Denmark) for 14 weeks. Every day, mice fed the HFHSD diet received a bacterial strain of the invention suspended in 10% skim milk (1x10 8 Oral doses of 10000 colony forming units [CFU]) were administered to the obese phenotype (HFHSD) control group and the lean phenotype (CD) control group in the same manner (n=10 mice per group). After 14 weeks, the mice were sacrificed by cervical dislocation and biological samples (blood, intestine, liver, etc.) were obtained.
[0131] Characterization of metabolic phenotype
[0132] Fasting basal blood glucose (weeks 8 and 10) was determined from blood drawn from the great saphenous vein using glucose test strips (Contour XT Bayer, Barcelona, Spain), and oral glucose tolerance was determined using an oral glucose test (OGTT, week 10), in which blood glucose was measured 15, 30, 60, and 120 min after an oral glucose overload (2 g / Kg) was given to mice fasted for 4 h. Plasma levels of insulin and gastrointestinal hormones such as glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) were also measured by multiplex (Mouse Metabolic Magnetic Bead Panel, Merck Chemical and Life Sciences, Madrid, Spain).
[0133] The bacterial object of the present invention can improve basal blood sugar ( Figure 1 a) and oral glucose tolerance ( Figure 1 b) According to these results, the bacteria also increased levels of the gastrointestinal hormones GLP-1 and PYY, which control post-meal blood sugar levels, by stimulating insulin secretion and reducing intake.
[0134] Analysis of liver energy metabolism
[0135] Considering the importance of the liver in maintaining blood glucose, energy metabolism in this tissue was also examined. To this end, by using qPCR, the mRNA levels of enzymes that limit glycation and lipid metabolism were analyzed, such as kinases that promote the storage of glucose in the form of glycogen under anabolic conditions ( Glucose production ; GcK, glucokinase); catabolic units of glucose-6-phosphatase (G6Pc) and phosphoenolpyruvate carboxylase 1 (PcK1), both involved in gluconeogenesis; lipase (lipoprotein lipase, LpL) that regulates triglyceride (Tg) homeostasis in plasma; acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), both enzymes involved in lipogenesis, hormone-sensitive lipase (HSL) that hydrolyzes TG (lipolysis) and carnitine palmitoyltransferase that limits fatty acid β-oxidation. Total RNA was isolated using TRIsure reagent according to the manufacturer's instructions (Bioline, Luckenwalde). 2 μg of total RNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (California, USA). cDNA (ng of cDNA detailed in Table 2 ) was amplified by qPCR in a Roche Light Cycler 480 instrument (Roche, Boulogne-Billancourt, France) using 480SYBR Green I Master (Mannheim, Germany) and forward (F) and reverse (R) primers (sequences in Table 2 ). The relative expression of mRNA was determined by method 2 -ΔΔCt calculate.
[0136] Table 2. Primer sequences used for analysis of gene expression by qPCR. Glucokinase (GcK), glucose 6 phosphatase catalytic unit (G6Pc), phosphoenolpyruvate carboxylase 1 (PcK1), lipoprotein lipase (LpL), acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), hormone-sensitive lipase (HSL), carnitine palmitoyltransferase (CPT1a), glucagon-like peptide receptor (GLP-1R), and peptide YY (PYY). F = forward; R = reverse.
[0137]
[0138]
[0139] Expression studies of these enzymes in the liver revealed significant effects on energy metabolism in obese mice, in particular, a decrease in the expression of LpL and ACC and an increase in the mRNA level of CPT1a were observed ( Figure 3 ). The bacteria prevented overexpression of CPT1a in the liver of obese mice, reaching levels seen in control mice fed a control diet; however, it had no significant effect on the expression of LpL and ACC. This result, together with the reduction in ACC expression, suggests that obese mice given the bacteria may have reduced levels of malonyl-CoA, a metabolite from glucose metabolism that inhibits CPT1a and thereby increases fatty acid oxidation. Bacteria-induced improvements in peripheral tissue glucose uptake ( Figure 2 a and b) were associated with normalization of fatty acid oxidation. In addition, the bacterium reduced, but not significantly, the mRNA level of G6Pc, an enzyme that limits glucose production.
[0140] Identification of intestinal signals mediating bacterial effects on glucose tolerance
[0141] The expression levels of the neuronal marker peripherin in the intestine were analyzed, which may indicate that the bacteria act through a gut-brain-liver mechanism and by stimulating vagal afferent nerves and GLP-1R (located in vagal afferent fibers) in the ileum. Although there were no significant changes in the expression of peripherin or GLP-1R in the ileum of obese mice compared with controls ( Figure 4 a and 4b), the bacteria increased the expression of peripherin by 8-fold and GLP-1R by two-fold, suggesting that the bacterial-induced increase in GLP-1 may stimulate the gut-brain-liver axis, in which stimulation of enteric innervation directs neural signals to the brain for integration in the hypothalamus to regulate energy homeostasis via efferent fibers.
[0142] Furthermore, the expression of proglucagon was reduced in the colon of obese mice compared with control mice ( Figure 4c), whereas the bacteria of the present invention are able to prevent this decrease and normalize the mRNA levels.
Claims
1. The Holdemanella biformis strain with the deposit number CECT 9752.
2. A composition comprising the strain according to claim 1.
3. The composition according to claim 2, wherein the composition additionally comprises at least one biologically active ingredient.
4. The composition according to claim 2 or 3, wherein the composition additionally comprises at least one microorganism different from the strain according to claim 1 or 2. The composition according to claim 4 , wherein the microorganism is a lactic acid bacterium.
6. The composition according to claim 2 or 3, wherein the composition is a pharmaceutical composition.
7. The composition according to claim 6, wherein the composition further comprises at least one pharmaceutically acceptable carrier and / or excipient.
8. The composition according to claim 6 or 7, wherein the composition is in a form suitable for oral, sublingual, nasal, bronchial, rectal, inhalation or parenteral administration.
9. A composition according to any one of claims 2 to 8, wherein the composition has 10 3 Up to 10 14 The concentration of the strain was expressed as colony forming units.
10. Use of the Holdemanella biformis strain with a deposit number of CECT 9752 in the manufacture of a composition for preventing and / or treating a disease associated with altered glucose metabolism selected from the group consisting of glucose intolerance, insulin resistance, metabolic syndrome, type 2 diabetes, gestational diabetes, and type 1 diabetes.
11. Use of the Holdemanella biformis strain with a deposit number of CECT 9752 or a composition comprising the Holdemanella biformis strain with a deposit number of CECT 9752 in the manufacture of an adjuvant.
12. Use according to claim 11, wherein the composition additionally comprises at least one biologically active ingredient.
13. Use according to any one of claims 10 to 12, wherein the composition additionally comprises at least one microorganism different from H. biformis CECT 9752.
14. The use according to claim 13, wherein the microorganism other than bacteria of the genus Holdemanella is a lactic acid bacterium.
15. Use according to any one of claims 10 to 12, wherein the composition is a pharmaceutical composition.
16. Use according to any one of claims 10 to 12, wherein the composition additionally comprises at least one pharmaceutically acceptable carrier and / or excipient.
17. Use according to any one of claims 10 to 12, wherein the composition is in a form suitable for oral, sublingual, nasal, bronchial, rectal, inhalation or parenteral administration.
18. The use according to any one of claims 10 to 12, wherein the composition has 10 3 Up to 10 14 The concentration of the strain was expressed as colony forming units.
